Under the agreement, Prometheus will receive an upfront payment of an undisclosed amount and could receive up to $420 million in milestone payments.
The companies will use Foundation Medicine's FoundationOne CDx test as the baseline to define a set of unique variants that the codeveloped assays will monitor.
Interpace Diagnostics subsidiary Interpace BioPharma will perform services worldwide, while Genecast will offer the services in China.
The partners are preparing to release two updates to Navify Tumor Board that support automatic importation of structured Foundation Medicine test reports.
Bruker signed a codevelopment and comarketing agreement with PreOmics for sample prep, and a partnership with Genedata for proteomics software.
Group K said that the partners are developing a RT-LAMP system for use at the point of care in resource-limited areas where real-time RT-PCR is not available.
The partnership gives each company non-exclusive access to the other's technology and may also include opportunities for transnational clinical trials.
The firms will partner on studies needed to support and secure US regulatory approval for the Elio tissue complete assay.
Weill Cornell will use Avalon GloboCare's exosome isolation system as part of a workflow to develop the exosomes for clinical studies.
The companies initially expect to incorporate a CDx for Incyte's pemigatinib into Foundation Medicine's existing FDA-approved assay, FoundationOne CDx.
Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.
The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.
A Washington Post columnist writes that she is skeptical about DNA-based diets.
In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.